TSR-033

· Tesaro, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TSR-033, covering 2024-02-12 to 2024-02-12. Get the full timeline:

Most recent: Clinical Trial Update: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors [Phase 1]

See pricing